These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 32504692)

  • 41. Efficacy of naltrexone on acetylcholine-induced alloknesis in atopic eczema.
    Heyer G; Groene D; Martus P
    Exp Dermatol; 2002 Oct; 11(5):448-55. PubMed ID: 12366698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel topical formulation containing strontium chloride significantly reduces the intensity and duration of cowhage-induced itch.
    Papoiu AD; Valdes-Rodriguez R; Nattkemper LA; Chan YH; Hahn GS; Yosipovitch G
    Acta Derm Venereol; 2013 Sep; 93(5):520-6. PubMed ID: 23474847
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans.
    Inan S; Cowan A
    Handb Exp Pharmacol; 2022; 271():275-292. PubMed ID: 33296031
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system.
    Umeuchi H; Togashi Y; Honda T; Nakao K; Okano K; Tanaka T; Nagase H
    Eur J Pharmacol; 2003 Sep; 477(1):29-35. PubMed ID: 14512095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.
    Morgenweck J; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
    Neuropharmacology; 2015 Dec; 99():600-9. PubMed ID: 26318102
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Topical nalfurafine exhibits anti-inflammatory and anti-pruritic effects in a murine model of AD.
    Elliott G; Vanwersch R; Soeberdt M; Metze D; Lotts T; Ständer S; Abels C
    J Dermatol Sci; 2016 Dec; 84(3):351-354. PubMed ID: 27665389
    [No Abstract]   [Full Text] [Related]  

  • 47. Role of spinal neurotransmitter receptors in itch: new insights into therapies and drug development.
    Cevikbas F; Steinhoff M; Ikoma A
    CNS Neurosci Ther; 2011 Dec; 17(6):742-9. PubMed ID: 20950328
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Therapy for chronic pruritus-light at the end of a long tunnel?].
    Pereira MP; Salzmann S; Ständer S; Staubach P; Metz M
    Internist (Berl); 2020 Oct; 61(10):1076-1086. PubMed ID: 32676722
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Doxepin affects acetylcholine induced cutaneous reactions in atopic eczema.
    Groene D; Martus P; Heyer G
    Exp Dermatol; 2001 Apr; 10(2):110-7. PubMed ID: 11260249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis.
    Tominaga M; Ogawa H; Takamori K
    J Invest Dermatol; 2007 Sep; 127(9):2228-35. PubMed ID: 17611580
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relieving the pruritus of atopic dermatitis: a meta-analysis.
    Sher LG; Chang J; Patel IB; Balkrishnan R; Fleischer AB
    Acta Derm Venereol; 2012 Sep; 92(5):455-61. PubMed ID: 22773026
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
    Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
    Front Immunol; 2020; 11():620098. PubMed ID: 33658996
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of naltrexone on spontaneous itch-associated responses in NC mice with chronic dermatitis.
    Maekawa T; Yamaguchi-Miyamoto T; Nojima H; Kuraishi Y
    Jpn J Pharmacol; 2002 Oct; 90(2):193-6. PubMed ID: 12419891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ZYKR1, a novel, potent, and peripherally selective kappa opioid receptor agonist reduces visceral pain and pruritus in animal models.
    Jain MR; Patel RB; Prajapati KD; Vyas P; Bandyopadhyay D; Prajapati V; Bahekar R; Patel PN; Kawade HM; Kokare DM; Pawar V; Desai R
    Eur J Pharmacol; 2022 Jun; 924():174961. PubMed ID: 35443192
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synergistic antipruritic effects of gamma aminobutyric acid A and B agonists in a mouse model of atopic dermatitis.
    Cevikbas F; Braz JM; Wang X; Solorzano C; Sulk M; Buhl T; Steinhoff M; Basbaum AI
    J Allergy Clin Immunol; 2017 Aug; 140(2):454-464.e2. PubMed ID: 28232084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Itch in Atopic Dermatitis.
    Kido-Nakahara M; Furue M; Ulzii D; Nakahara T
    Immunol Allergy Clin North Am; 2017 Feb; 37(1):113-122. PubMed ID: 27886901
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New therapies for controlling atopic itch.
    Furue M; Kadono T
    J Dermatol; 2015 Sep; 42(9):847-50. PubMed ID: 26332459
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
    Ständer S; Yosipovitch G
    Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel drugs for the treatment of chronic pruritus.
    Pereira MP; Ständer S
    Expert Opin Investig Drugs; 2018 Dec; 27(12):981-988. PubMed ID: 30426802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.